Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization

Vaccine

Volumn 17, Issue 2, 1999, Pages 110-113

  Keddy, Karen H ^a   Klugman, Keith P ^a   Hansford, C Frank ^b   Blondeau, Christine ^c   Bouveret Le Cam, Nancy N ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Darie Jambert St   (South Africa)

^c Pasteur Merieux Serums et Vaccins   (France)

Author keywords

Persistence; Salmonella typhi; Typhoid vaccine; Vi capsular polysaccharide

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TYPHOID VACCINE;

ADOLESCENCE; ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; ENDEMIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SALMONELLA TYPHI; SOUTH AFRICA; TYPHOID FEVER;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; SOUTH AFRICA; TIME FACTORS; TYPHOID-PARATYPHOID VACCINES;

EID: 0032889959     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00160-1     Document Type: Article

References (15)

1. Klugman KP, Gilbertson IT, Koornhof HJ, et al. and the Vaccination Advisory Committee, Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet, 1987, II, 1165-1169.
2. Acharya I.L., Lowe C.U., Thapa R.et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. NEJM. 317:1987;1101-1104.
3. Mirza N.B., Wamola I.A., Estambale B.A., Mbithi E., Poillet M. Typhim Vi against typhoid fever: a clinical trial in Kenya. East African Medical Journal. 72:1995;162-164.
4. Data on file. Pasteur Mérieux Typhim Vi expert report. A/093 IC3/02.96.
5. Klugman KP, Vosloo H, Arntzen L, Koornhof HJ. Prevention of typhoid fever by single dose capsular polysaccharide vaccination - 2 year results. In Travel Medicine, eds R. Steffen, H.O. Lobel, J. Hayworth and D.J. Bradley. Springer-Verlag, Berlin, 1989, pp. 243-247.
6. Klugman K.P., Koornhof H.J., Robbins J.B., Bouveret le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 14:1996;435-438.
7. Plotkin S.A., Bouveret le Cam N.N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Archives of Internal Medicine. 155:1995;2293-2299.
8. Mufson M.A., Krause H.E., Schiffman G., Hughey D.F. Pneumococcal antibody levels one decade after immunization of healthy adults. American Journal of Medical Sciences. 293:1987;279-284.
9. Bhatnagar S.S. Vi agglutination in the diagnosis of typhoid fever and the typhoid carrier condition. BMJ. 2:1938;1195-1198.
10. Nolan C.M., White P.C., Feeley J.C., Brown S.L., Hambie E.A., Wong K.-H. Vi serology in the detection of typhoid carriers. Lancet. 1:1981;583-585.
11. Lanata C.F., Ristori C., Jiminez L.et al. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet. 2:1983;441-443.
12. Edelman R., Levine M.M. Summary of an international workshop on typhoid fever. Reviews in Infectious Diseases. 8:1986;329-349.
13. Musher D.M., Groover J.E., Watson D.A.et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. Journal of Investigative Medicine. 45:1997;57-68.
14. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W.M., Moxon E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. Journal of Infectious Diseases. 171:1995;93-98.
15. Slack M.P.E. Invasive Haemophilus influenzae disease: the impact of Hib immunization (editorial). Journal of Medical Microbiology. 42:1995;75-77.